Multiple Myeloma

Phase 1 data show that anti-BCMA CAR-T cells can be generated directly within a patient without a need for leukapheresis and lymphodepleting chemotherapy.

Phase 1/2 data may warrant further investigation of belantamab mafodotin plus lenalidomide/dexamethasone in randomized controlled studies.

Data from a phase 3 trial may support the role of carfilzomib in the upfront treatment setting for patients with multiple myeloma.

Teclistamab/daratumumab is one of the most exciting combinations seen in relapsed/refractory multiple myeloma, said María-Victoria Mateos, MD, PhD.

The CAREMM-001 study may offer a glimpse into a potential future in which the therapeutic sequence of multiple myeloma is fundamentally reimagined.

A panel of experts convened to explore the practical integration of BCMA-directed bispecific antibodies into clinical care for patients with multiple myeloma.

The adoption of bispecific antibodies in the community setting remains a great unmet need in multiple myeloma, according to Rajshekhar Chakraborty, MD.

Investigators will present detailed findings from the phase 3 SUCCESSOR-2 trial at a later medical meeting.

The Commissioner’s National Priority Voucher has been granted by the FDA to teclistamab plus daratumumab hyaluronidase-fihj in relapsed/refractory multiple myeloma.

If approved, iberdomide plus daratumumab/dexamethasone would offer patients more choices, according to Sagar Lonial, MD, FACP, FASCO.

Data from a phase 1b/2 study may support further assessment of AZD0120 in earlier treatment settings for patients with multiple myeloma.

Investigators of the phase 2 MOMENTUM trial will enroll and assign approximately 100 patients to receive cemsidomide at 100 µg.

Data from the EXCALIBER-RRMM trial support the application for iberdomide plus standard therapy in this relapsed/refractory multiple myeloma population.

Developing small molecules that target t(4;14) will be important in multiple myeloma care, according to Saad Z. Usmani, MD, MBA, FACP, FASCO.

Discover how stem cell transplant still deepens myeloma remission, guided by MRD and paired with CAR‑T, bispecifics, and smarter maintenance.

In the future, the multiple myeloma field may gradually shift away from a continuous therapy model to more fixed-duration approaches.

From key clinical trial updates to reports on treatment disparities, the 2026 Tandem Meetings saw several critical developments in multiple myeloma.

Research may support the development of more comprehensive risk-stratification models accounting for different tumor-intrinsic factors.

Potential FDA approval of teclistamab plus daratumumab may offer another option in the multiple myeloma armamentarium, said Surbhi Sidana, MD.

Additional translational research may help inform the design of next-generation therapies for patients with multiple myeloma, said Manoj Bhasin, PhD, MS.

A new guideline from ASCO and Ontario Health conditionally recommends the use of daratumumab for patients with high-risk smoldering multiple myeloma.

Data from the phase 3 CEPHEUS trial support the approval of the daratumumab-based regimen among patients with newly diagnosed multiple myeloma.

Investigators are currently assessing IBI3003 among patients with relapsed/refractory multiple myeloma in a phase 1/2 trial.

Findings show that age also represents an important driver for select pathologic genomic events differing at the presentation of disease by sex.

According to the FDA, randomized trials are preferred when assessing MRD to support accelerated approvals in multiple myeloma.